Biomarin is purchasing Prosensa for approximately $840 million.

On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company's lead drug candidate for Duchenne Muscular Dystrophy.

A medical researcher turned biotech analyst highlights several companies with unique diagnostic and therapeutic technologies.

Shares of Sarepta Therapeutics (SRPT) tumbled as much as 28% after it updated its phase 2b data from its Eteplirsen study. But the stock fell for the wrong reasons and should still be a strong buy. Here's why...

To pay for the overnight Hong Kong incorporated Chinese oilfield services company, in which Schlumberger Ltd owns 20%, I halved my holdings in Yandex, the Black Sea internet services provider, and in Singapore-based Indian REIT Ascendas India Trust. Plus more from Africa, Britain, Cuba, Finland, The Netherlands, Spain, Belgium, Canada, and Israel.